Industry Experts - Market Research Reports, Industry Analysis, Custom Research

  Introduction to Biosimilars Biosimilars are biologic drugs that closely resemble approved biologics, known as reference products, without any clinically meaningful differences in terms of safety, purity, or effectiveness. Developed using living systems such as yeast, bacteria, or animal cells, biosimilars are inherently complex and sensitive to manufacturing changes, distinguishing them from generic drugs, which are precise chemical replicas of small-molecule drugs. These products span multiple therapeutic categories, including monoclonal antibodies used in cancer and autoimmune conditions, hematopoietic agents like filgrastim that aid in blood cell production, hormonal treatments such as insulin and growth hormones, and anti-inflammatory medications for conditions like rheumatoid arthritis. Expanding Applications of Biosimilars Biosimilars play a crucial role in managing various diseases, including oncology treatments such as trastuzumab for cancer therapy, blood disorders like...

Industry Experts, Inc. published the new 2021 version of its global market report on Biosimilars. The new version of the report entitled " Global Biosimilars Market – Products, Applications and Regulations " reveals that the global market for Biosimilars application in Oncology therapeutics is the largest in 2020 closely followed by Autoimmune Disorders. Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies' commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships. The solution to 'build versus buy' is no longer driven by the size, scale, and cost of a sales force leadi...